Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Europe: 4 Urban communities for a Paramount Social Experience - 2Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- 3New science points to 4 distinct types of autism
- 4The many ways that baking is winter therapy. With a delicious ending
- 5Scientists document a death from a meat allergy tied to certain ticks
- Doctors thought he had cancer. An offhand suggestion led to a rare diagnosis.
- 'Crammed into a cell with vermin at New Year'
- I was about to film a movie with Glen Powell when my hair started falling out in clumps. Alopecia has made me unrecognizable as an actor.
- Virtual reality opens doors for older people to build closer connections in real life
- Volcanic eruption led to the Black Death, new research suggests
- Second doctor in Matthew Perry overdose case sentenced to home confinement
- When darkness shines: How dark stars could illuminate the early universe
- Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says
- In blow to Lula, Brazil Congress revives controversial environmental bill
